Statement of Changes in Beneficial Ownership (4)
November 02 2021 - 3:07PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Javitt Daniel C. |
2. Issuer Name and Ticker or Trading Symbol
NRX Pharmaceuticals, Inc.
[
NRXP
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O NRX PHARMACEUTICALS, INC., 1201 NORTH MARKET STREET, SUITE 111 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/16/2021 |
(Street)
WILMINGTON, DE 19801
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 7/16/2021 | | G | | 434594 | D | (1) | 13537270 | I | By Glytech LLC (2) |
Common Stock | 7/16/2021 | | G | | 434594 | D | (1) | 13102676 | I | By Glytech LLC (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Irrevocable gift by way of transfer to certain trusts established for the benefit of the Reporting Person's immediate family members. Neither the Reporting Person nor Glytech LLC received any compensation in respect of such transfers. Upon completion of such transfers, both the Reporting Person and Glytech LLC ceased to have any beneficial ownership or other interest in the shares subject to the transfers. |
(2) | Held by Glytech, LLC of which the Reporting Person is the sole owner. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Javitt Daniel C. C/O NRX PHARMACEUTICALS, INC. 1201 NORTH MARKET STREET, SUITE 111 WILMINGTON, DE 19801 |
| X |
|
|
Signatures
|
/s/ Daniel Javitt | | 11/2/2021 |
**Signature of Reporting Person | Date |
Big Rock Partners Acquis... (NASDAQ:BRPAU)
Historical Stock Chart
From Apr 2024 to May 2024
Big Rock Partners Acquis... (NASDAQ:BRPAU)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Big Rock Partners Acquisition Corporation (NASDAQ): 0 recent articles
More Nrx Pharmaceuticals, Inc. News Articles